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631REPLY: 18F-FDG Imaging in Patients With
“Suspected,” But Not “Proven,” SarcoidosisWe thank Drs. Njeim, Bogun, and Crawford for
their interest in our study (1). We agree that in the
absence of histological conﬁrmation of sarcoidosis,
it is possible that there may be other chronic inﬂam-
matory processes that could have a similar presenta-
tion, hence, our designation in the title “suspected
cardiac sarcoidosis.” Patients with this constellation of
ﬁndings who lack a histological diagnosis are as
common as those with a histological diagnosis and
raise difﬁcult management issues. We would note
the following: 1) the vast majority of events in patients
with abnormal positron emission tomography (PET)
studies occurred in patients with known or a high
likelihood of cardiac sarcoidosis (see the Online Ap-
pendix in our original paper [1]); 2) none of the patients
in our study had known acute myocarditis (e.g.,
elevated cardiac enzymes), and although scar from
prior episodes of myocarditis may cause arrhythmias,
this would not result in increased FDG uptake; and 3)
none of the patients with increased FDG had other
potential alternative reasons for such ﬁndings such as
coronary artery disease or any known systemic in-
ﬂammatory or rheumatologic disease. Even in the
absence of a histological diagnosis (which cannot
always be obtained in cardiac sarcoidosis), abnormal
PET ﬁndings were associated with a substantial in-
crease in the rate of death/ventricular tachycardia.
The high event rate observed in our study is in
part due to referral bias, because our center is a
quaternary care center for advanced heart failure
and arrhythmias. As expected, our study therefore
included patients with a prior history of arrhythmias.
It is also noteworthy that the high event rate observed
in our study is in keeping with data from Schuller
et al. (2), who reported that appropriate implantable
cardioverter-deﬁbrillator (ICD) therapies occurred in
36 (32%) of 112 patients with cardiac sarcoidosis over
a mean of 29 months, and from Betensky et al. (3),
who reported ICD therapies in 17 (38%) of 45 patients
with cardiac sarcoidosis followed over a median of
2 years. In regard to events in patients with normal
PET, we would point out that we used PET only to
evaluate for inﬂammation or scar, and that it does
not exclude nonischemic cardiomyopathy. In fact,
all of the 6 patients with a normal PET scan who
experienced events had systolic dysfunction. There-
fore, if we were to deﬁne a “normal PET” as also
having a normal left and right ventricular function,
there would be zero events in this category.
In regard to the low prevalence of extracardiac
sarcoidosis, it is important to note that we reportedthe frequency of extracardiac FDG uptake (which
represents active inﬂammation) as distinguished
from other radiological evidence of disease that
may represent scar from inactive disease. However,
even when accounting for the fact that patients
without extracardiac FDG uptake may have had prior
extracardiac sarcoidosis, we do believe that the
presence of isolated cardiac sarcoidosis is under-
recognized. In part, this is because prior clinical
criteria, as well as most prior imaging studies, have
only included patients with conﬁrmed extracardiac
disease. We believe that future criteria should
address the fact that cardiac sarcoidosis can be pre-
sent (and therefore should be diagnosed) even in
patients without extracardiac disease. We also agree
that a prospective study is needed to deﬁne the role
of PET in selection of therapy for this challenging
group of patients.*Ron Blankstein, MD
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Cardiac Troponin T
Testing Time Is Also a Learning TimeHigh-sensitivity cardiac troponin T (hs-cTnT) is
excellent for the early diagnosis of myocardial
infarction (1). In a recent issue of the Journal,
Bandstein et al. (2) validated again the outstanding
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632value of hs-cTnT to rule out myocardial infarction in
chest pain patients in the emergency department.
After investigating 14,636 patients who sought med-
ical attention for chest pain, the investigators
concluded that patients with chest pain who have an
initial hs-cTnT level of <5 ng/l and no signs of
ischemia on an electrocardiogram (ECG) can be safely
discharged directly from the emergency department.
This work is very meaningful for relieving medical
burden.
However, the original study did not mention a very
common issue—the duration of the onset of chest
pain. Although the time of the ﬁrst detectable low-
level elevation of hs-cTnT has become shorter
compared with conventional troponin T, it still needs
90 to 180 min after the event (3). This means that
within about 1.5 to 3 h after the onset of chest pain,
the hs-cTnT level may be undetectable even if
the patient is having a myocardial infarction. Corre-
spondingly, in the original study, 15 patients with
undetectable hs-cTnT and no signs of ischemia on
the ECG had a ﬁnal diagnosis of myocardial infarc-
tion, of which 13 patients had hs-cTnT <5 ng/l within
3 h after the onset of chest pain, and 11 of the 13
patients were found to have hs-cTnT elevation after
3 h (2). Therefore, we presumed that the negative
predictive value for myocardial infarction with un-
detectable hs-cTnT within 3 h after the onset of chest
pain was much lower than what the original study
reported. Given a lot of patients with chest pain are
going to the emergency department within 3 h (4),
the low negative predictive value of hs-cTnT might
render a number of missed diagnoses. As a conse-
quence, we considered that the conclusion of the
original study was too arbitrary, which might inad-
vertently mislead clinicians into making mistakes.
Besides, a diurnal hs-cTnT rhythm was detected by
Klinkenberg et al. (5). The diurnal variation of hs-
cTnT was characterized by peak concentrations dur-
ing the morning hours (by 08:30 h), gradually
decreasing values during the daytime (until 20:30 h),
and rising concentrations during the nighttime (until
08:30 h the next day) (5), which might also affect
the accuracy of hs-cTnT on predicting myocardial
infarction.
In conclusion, we think the utilization of hs-cTnT
should be combined with the duration of the events
and the diurnal hs-cTnT rhythm.Wei Liu, MD
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in the Emergency
Department and Risk of
Myocardial InfarctionWe read with great interest the recent publication by
Bandstein et al. (1), and congratulate the authors on
their thought-provoking results. If the ﬁndings are
substantiated, then such an approach could have a
major impact on the resources and time required to
investigate patients with possible cardiac chest pain.
The conclusion is emphatically worded: “All patients
with chest pain who have an initial hs-cTnT level
of <5 ng/l and no signs of ischemia on ECG [electro-
cardiogram] have a minimal risk of MI [myocardial
infarction] or death within 30 days and can be safely
discharged directly from the ED [emergency depart-
ment].” We therefore ask the authors whether they
believe that such an investigative approach is ready for
widespread international uptake without further
external validation using robust recruitment and
follow-up processes? The impressive size of the study
was achievable only by making a number of method-
ological compromises that we shall discuss in the
following text.
First, this was an observational trial, and no
patients were actually discharged by virtue of their
ﬁndings. In fact, at least 21% were hospitalized using
